Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Obstetrics and Gynaecology"
DOI: 10.1080/01443615.2022.2049724
Abstract: Abstract The aim of treatment in recurrent or refractory epithelial ovarian cancer is palliation. In a patient with platinum-resistant status, several chemotherapy regimens have been reported with similar response rates. Among these agents, the oral… read more here.
Keywords: recurrent refractory; cancer; epithelial ovarian; ovarian cancer ... See more keywords
Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000022637
Abstract: Abstract Introduction: Small cell lung cancer (SCLC) is an aggressive malignancy that progresses rapidly and easily relapses. To the best of our knowledge, advances have been minimal for decades and the first-line treatment is still… read more here.
Keywords: small cell; treatment; oral etoposide; hemodialysis ... See more keywords
A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.565384
Abstract: Introduction We performed this clinical trial to evaluate the efficacy and safety of apatinib and oral etoposide in patients with HER2-negative locally advanced or metastatic breast cancer (MBC). Methods Patients with HER2-negative MBC previously treated… read more here.
Keywords: oral etoposide; breast; apatinib oral; breast cancer ... See more keywords
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14092114
Abstract: Simple Summary Oral etoposide (VP16), an inhibitor of topoisomerase-II, has demonstrated clinical activity in metastatic breast cancer (MBC). To our knowledge, oral VP16 combined with trastuzumab (VP16-T) in HER2+ MBC has not been evaluated before.… read more here.
Keywords: breast; oral etoposide; her2 mbc; vp16 ... See more keywords